Line of Credit
|12 Months Ended|
Dec. 31, 2021
|Debt Disclosure [Abstract]|
|Line of Credit||
Note 6 – Line of Credit
On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $0.3 million strategic equity investment in the Company and agreed to make a $0.8 million purchase order line of credit facility available to the Company. The principal balance outstanding under the line of credit, which bears interest at the rate of prime plus 2% per annum, amounted to $31,000 as of December 31, 2021 and 2020, respectively.
Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef